COSMO Pharmaceuticals N.V.

COPN

Equity

ISIN NL0011832936 / Valor 32590356

SIX Swiss Exchange (2024-09-18)

CHF 77.20-1.40%

COSMO Pharmaceuticals N.V.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

COSMO Pharmaceuticals N.V. is a pharmaceutical company with a portfolio of 6 approved drugs and 2 approved medical devices. The company focuses on identifying unmet medical needs, managing product development, and obtaining regulatory approval for its products. COSMO licenses its approved products to partners with strong marketing and sales expertise, while also providing services related to the production of pharmaceutical products such as assessment of manufacturing processes, technology transfer, evaluation of product stability, testing and release to the market, and drafting necessary documentation for product registration.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first half of 2024, COSMO Pharmaceuticals N.V. reported record revenues of €136.2 million, a significant increase from €43.7 million in the same period last year. This growth was primarily driven by a $100 million upfront payment from Medtronic related to the expansion of their artificial intelligence partnership.

Operating Profit

COSMO Pharmaceuticals N.V. achieved an operating profit of €87.0 million in H1 2024, a substantial rise compared to €7.1 million in H1 2023. This increase reflects the company's successful revenue growth and effective cost management strategies.

Net Cash Inflow

Net cash inflow from operating activities for COSMO Pharmaceuticals N.V. in the first half of 2024 was €99.2 million, a significant improvement from €15.5 million in the same period last year. This strong cash generation underscores the company's robust financial health.

GI Products and CDMO Business

Revenues from COSMO Pharmaceuticals N.V.'s GI products grew by 4.3% to €21.4 million in H1 2024. Additionally, the company's contract development and manufacturing organization (CDMO) business saw a 9.3% increase in revenue, reaching €8.9 million.

2024 Financial Guidance

COSMO Pharmaceuticals N.V. has confirmed its 2024 financial guidance, projecting revenues in the range of €260 million to €270 million and operating profit between €159 million and €169 million. This outlook reflects the company's confidence in its ongoing growth and profitability.

Summarized from source with an LLMView Source

Key figures

83.6%1Y

-6.42%3Y

-5.62%5Y

Performance

30.2%1Y

31.9%3Y

32.5%5Y

Volatility